<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01600625</url>
  </required_header>
  <id_info>
    <org_study_id>4-2011-0830</org_study_id>
    <nct_id>NCT01600625</nct_id>
  </id_info>
  <brief_title>Effects of Minocycline on Cytokine Levels in Severe Meibomian Gland Dysfunction</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      One of the important factors in obtaining successful outcomes when treating severe meibomian
      gland dysfunction (MGD) is to control the existing ocular and eyelid inflammation. Thus, in
      previous studies, topical and systemic antibiotics with anti-inflammatory function, such as
      topical azithromycin, systemic tetracycline, doxycycline and minocycline, have been used to
      treat severe MGD. In this study, minocycline which had the fewest side effects was used to
      evaluate the effect on cytokine levels in severe MGD. At study initiation, all patients
      completed an Ocular Surface Disease Index (OSDI) questionnaire and had an ocular surface,
      tear, and meibomian gland evaluation that consisted of fluorescein tear break-up time (TBUT),
      Schirmer test, corneal and conjunctival fluorescein staining, microscopic examination of lid
      margins and meibomian glands, and tear cytokine levels. All measurements except tear cytokine
      levels were conducted in the same manner before treatment, after 1 month, and after 2 months
      of treatment. Tear cytokine levels were evaluated before treatment and after 2 months of
      treatment. The aim of this research was to determine the concentration of inflammatory
      cytokines in the tears of patients with MGD and to compare the cytokine levels, corresponding
      clinical responses, and ocular symptoms before and after 2 months of treatment with oral
      minocycline.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of inflammatory tear cytokine levels</measure>
    <time_frame>before treatment and after 2 months of treatment</time_frame>
    <description>Thirty microliters of phosphate-buffered saline will be injected into the inferior conjunctival sac using a micropipette. Approximately 20 μL tear fluid and buffer will be collected with a micropipette.
Cytokines are measured using the BDTM Cytometric Bead Array (CBA) (BD Bioscience, San Jose, CA). The cytokines analyzed were interleukin (IL)-1β, IL-6, IL-7, IL-8, IL-12p70, IL-17α, interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and monocyte chemotactic protein-1 (MCP-1). Flow cytometry will be performed using the BDTM LSRII system (BD Bioscience, San Jose, CA).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>Minocycline treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral minocycline hydrochloride treatment</intervention_name>
    <description>Orally received 50 mg minocycline (Minocin, SK chemical, Seoul, Korea) twice a day for 2 months treatment</description>
    <arm_group_label>Minocycline treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with stage 3 or 4 meibomian gland dysfunction

          -  moderate or marked symptoms of ocular discomfort, itching, or photophobia with
             limitations of activities

          -  moderate or severe meibomian gland dysfunction clinical signs

          -  mild to moderate conjunctival and peripheral corneal staining or increased
             conjunctival and corneal staining, including central staining

          -  increased signs of inflammation : moderate or severe conjunctival hyperemia,
             phlyctenulae

        Exclusion Criteria:

          -  history of previous ocular or intraocular surgery

          -  evidence of acute or chronic infections or inflammation of the cornea and conjunctiva

          -  ocular allergy

          -  autoimmune disease

          -  history of intolerance or hypersensitivity to any component of the study medications

          -  use of topical ocular medications

          -  wearing contact lenses during the study period

          -  presence of current punctal occlusion

          -  pregnancy

          -  lactating women

          -  children
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Hom MM, Martinson JR, Knapp LL, Paugh JR. Prevalence of Meibomian gland dysfunction. Optom Vis Sci. 1990 Sep;67(9):710-2.</citation>
    <PMID>2234831</PMID>
  </results_reference>
  <results_reference>
    <citation>Schaumberg DA, Nichols JJ, Papas EB, Tong L, Uchino M, Nichols KK. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):1994-2005. doi: 10.1167/iovs.10-6997e. Print 2011 Mar. Review.</citation>
    <PMID>21450917</PMID>
  </results_reference>
  <results_reference>
    <citation>Knop E, Knop N, Millar T, Obata H, Sullivan DA. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):1938-78. doi: 10.1167/iovs.10-6997c. Print 2011 Mar. Review.</citation>
    <PMID>21450915</PMID>
  </results_reference>
  <results_reference>
    <citation>Tomlinson A, Bron AJ, Korb DR, Amano S, Paugh JR, Pearce EI, Yee R, Yokoi N, Arita R, Dogru M. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):2006-49. doi: 10.1167/iovs.10-6997f. Print 2011 Mar. Review.</citation>
    <PMID>21450918</PMID>
  </results_reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2012</study_first_submitted>
  <study_first_submitted_qc>May 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2012</study_first_posted>
  <last_update_submitted>March 4, 2014</last_update_submitted>
  <last_update_submitted_qc>March 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>meibomian gland dysfunction</keyword>
  <keyword>inflammatory tear cytokine</keyword>
  <keyword>minocycline</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

